<DOC>
	<DOC>NCT01005901</DOC>
	<brief_summary>A study to assess the safety, tolerability and efficacy of NVA237 versus placebo in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD).</brief_summary>
	<brief_title>A Study to Assess the Safety, Tolerability and Efficacy of NVA237 Versus Placebo</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases, Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
	<mesh_term>Bromides</mesh_term>
	<mesh_term>Glycopyrrolate</mesh_term>
	<criteria>1. Diagnosis of COPD (moderatetosevere as classified by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) Guidelines, 2008) and: Smoking history of at least 10 packyears Postbronchodilator FEV1 &lt; 80% and â‰¥ 30% of the predicted normal value Postbronchodilator FEV1/FVC (forced vital capacity) &lt; 70% 1. Patients who have had a lower respiratory tract infection within 6 weeks prior to Visit 1 2. Patients with concomitant pulmonary disease 3. Patients with a history of asthma 4. Any patient with lung cancer or a history of lung cancer 5. Patients with a history of certain cardiovascular comorbid conditions 6. Patients with a known history and diagnosis of alpha1 antitrypsin deficiency 7. Patients in the active phase of a supervised pulmonary rehabilitation program 8. Patients contraindicated for tiotropium or ipratropium treatment or who have shown an untoward reaction to inhaled anticholinergic agents Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>COPD</keyword>
	<keyword>NVA</keyword>
	<keyword>FEV1</keyword>
</DOC>